Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.
Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.
复制标题
DOI：
10.1038/bjc.2011.295
复制
发表时间：
2011-08-23
影响因子：
8.8
通讯作者：
Jirstrom, K.
中科院分区：
文献类型：
--
作者：
Larsson, A.;Johansson, M. E.;Wangefjord, S.;Gaber, A.;Nodin, B.;Kucharzewska, P.;Welinder, C.;Belting, M.;Eberhard, J.;Johnsson, A.;Uhlen, M.;Jirstrom, K.
Podocalyxin-like 1 （PODXL）是一种细胞粘附糖蛋白和干细胞标志物，在几种癌症中与侵袭性肿瘤表型和不良预后相关。在这项研究中，我们研究了PODXL在结直肠癌（CRC）中的表达对预后的影响。利用组织微阵列和免疫组织化学技术，对536例CRC病例的PODXL表达进行了前瞻性、基于人群的队列研究。采用Kaplan-Meier分析和Cox比例风险模型评估PODXL表达对癌症特异性生存期（CSS）和总生存期（OS）的影响。高PODXL表达与不良的临床病理特征显著相关，较短的CSS(风险比(HR)=1.98；95%置信区间（CI） 1.38 ~ 2.84， P<0.001)和5年OS (HR=1.85; 95% CI 1.29 ~ 2.64， P=0.001)；后者在多变量分析中仍然显著（HR=1.52; 95% CI 1.03-2.25， P=0.036）。此外，在治疗切除的III期（T1-4、N1-2、M0）患者（n=122）中，伴有高PODXL表达的肿瘤，证实了辅助化疗的显着益处（多变量分析中，CSS的p交互作用=0.004,5年OS的p交互作用= 0.015）。Podocalyxin-like 1表达是结直肠癌预后不良的独立因素。我们的研究结果还表明，PODXL可能是一个有用的标志物，可用于对患者进行辅助化疗的分层。
Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has been associated with an aggressive tumour phenotype and poor prognosis in several forms of cancer. In this study, we investigated the prognostic impact of PODXL expression in colorectal cancer (CRC). Using tissue microarrays and immunohistochemistry, PODXL expression was evaluated in 536 incident CRC cases from a prospective, population-based cohort study. Kaplan–Meier analysis and Cox proportional hazards modelling were used to assess the impact of PODXL expression on cancer-specific survival (CSS) and overall survival (OS). High PODXL expression was significantly associated with unfavourable clinicopathological characteristics, a shorter CSS (hazard ratio (HR)=1.98; 95% confidence interval (CI) 1.38–2.84, P<0.001) and 5-year OS (HR=1.85; 95% CI 1.29–2.64, P=0.001); the latter remaining significant in multivariate analysis (HR=1.52; 95% CI 1.03–2.25, P=0.036). In addition, in curatively resected stage III (T1–4, N1–2, M0) patients (n=122) with tumours with high PODXL expression, a significant benefit from adjuvant chemotherapy was demonstrated (pinteraction =0.004 for CSS and 0.015 for 5-year OS in multivariate analysis). Podocalyxin-like 1 expression is an independent factor of poor prognosis in CRC. Our results also suggest that PODXL may be a useful marker to stratify patients for adjuvant chemotherapy.
登录
查看更多内容
影响因子：
3.7
作者：
Nielsen JS;Graves ML;Chelliah S;Vogl AW;Roskelley CD;McNagny KM
通讯作者：
McNagny KM
DOI：
10.1084/jem.194.1.13
发表时间：
2001-07-02
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Doyonnas R;Kershaw DB;Duhme C;Merkens H;Chelliah S;Graf T;McNagny KM
通讯作者：
McNagny KM
影响因子：
6
作者：
Hsu, Yung-Ho;Lin, Wei-Ling;Jou, Tzuu-Shuh
通讯作者：
Jou, Tzuu-Shuh
影响因子：
3.9
作者：
HASE, K;SHATNEY, C;VIERRA, M
通讯作者：
VIERRA, M
影响因子：
7.5
作者：
Chen, X;Higgins, J;So, S
通讯作者：
So, S